L. reuteri
Dietary SupplementDietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
NCT Number: NCT05512234
This is a double-blind, multi-center, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying time.
Interested in participating?
Request Info3 week–8 week
All sexes
Interventional
Not applicable
Atlantia Clinical Trials, Cork, Ireland
Prevalence of infantile colic varies according to the definition used but estimates range between 5 % and 26 % of the infant population. To differentiate colic from other, more serious conditions it should be characterized by several clinical features. Infant colic is often accompanied by flushing the face, frown, tensing of the abdomen, clenching of the fists, and drawing up the leg, frequent, prolonged, and intense crying or fussiness in a healthy infant. Even though infant colic is benign and usually self-limiting condition it is a source of major distress for the infant, parents, family, and health care givers.
Despite infant colic occurs frequently, little agreement has been reached on the definition, pathogenesis, or the optimal management strategy for infant colic. Recent systematic reviews and meta-analyses showed that probiotic L. reuteri DSM 17938 supplementation significantly lowered the number of hours of crying and fussing daily. A significant peak effect was seen at 3 weeks in most studies. Interestingly, babies with infant colic were found to have increased evidence of gut inflammation, as evidenced by high levels of the antimicrobial peptide fecal calprotectin; also, the levels of fecal calprotectin declined significantly as the condition resolved.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
Time frame: From baseline to Day 7
Change in daily crying and fussing time measured by Baby Day Diary
Time frame: From baseline to Day 3, Day 5, Day 14, Day 21
Change in mean daily crying and fussing time measured by Baby Day Diary
Time frame: From baseline to Day 3, Day 5, Day 7, Day 14, Day 21
Change in mean daily crying time measured by Baby Day Diary
Time frame: From baseline to Day 3, Day 5, Day 7, Day 14, Day 21
Proportion of responders defined as reduction of daily average crying time with 50 % compared to baseline
Time frame: From baseline to Day 7 and Day 21
Change in family QoL measured by the PedsQL Family Impact Module (Acute) - Total Score
Time frame: From baseline to Day 3, Day 5, Day 7, Day 14, Day 21
Change in mean sleeping time measured by Baby Day Diary
Time frame: From baseline to Day 7 and Day 21
Change in maternal depression measured by the Edinburgh Postnatal Depression Scale Total Score
Contact information is provided by the study sponsor or research team.
BioGaia AB
Industry
A Double-blind, Mylti-center, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06031025
Colic, Colic, Infantile
Roma, Italy
View Trial DetailsNCT07254520
Colic, Colic, Infantile
Yalova, Turkey (Türkiye)
View Trial DetailsNCT07236242
Colic, Colic, Infantile
Angra do Heroísmo, Azores, Portugal
View Trial DetailsNCT07121062
Atopic Dermatitis (Eczema), Colic
Southampton, United Kingdom
View Trial Details